- Molecular NameEptifibatide
- Synonymeptifibatide; Integrelin; Intrifiban
- Weight831.977
- Drugbank_IDDB00063
- ACS_NO188627-80-7
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)-1.15
- pkaN/A
- LogD (pH=7, predicted)-3.65
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)0.04
- LogSw (predicted, AB/LogsW2.0)0.2
- Sw (mg/ml) (predicted, ACD/Labs)911.77
- No.of HBond Donors13
- No.of HBond Acceptors20
- No.of Rotatable Bonds11
- TPSA374.49
- StatusFDA approved
- AdministrationIV only
- PharmacologyAn antiplatelet drug that selectively blocks the platelet glycoprotein IIb/IIIa receptor.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability0.0
- Protein binding25.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThe majority of the drug excreted in the urine as eptifibatide, deamidated eptifibatide, and other, more polar metabolites.
- Half life2.5 h
- ExcretionRenal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityBleeding is the most importand advese effect of Eptifibatide. Hypoteinsion is the most serious non-bleeding event. Other adverse effects reported include intracranial hemorragie and stroke, thrombocytopenia, allergic reactions.
- LD50 (rat)N/A
- LD50 (mouse)N/A